Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKBA NASDAQ:BTMD NASDAQ:MLYS NYSE:ZYME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$3.72+1.1%$3.63$1.07▼$4.08$967.81M0.963.02 million shs3.02 million shsBTMDbiote$3.89-4.4%$4.01$3.04▼$7.34$222.67M1.2184,602 shs120,114 shsMLYSMineralys Therapeutics$13.66-3.5%$14.52$8.24▼$18.38$922.23M-0.29637,447 shs1.11 million shsZYMEZymeworks$12.57+0.1%$12.82$9.03▼$17.70$875.92M1.19537,092 shs637,973 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics+1.09%+4.49%+2.48%+51.84%+169.57%BTMDbiote-4.42%-9.95%-7.16%+11.78%-50.95%MLYSMineralys Therapeutics-3.46%-4.61%-4.48%-11.41%+10.25%ZYMEZymeworks+0.08%-5.70%-2.48%-3.01%+20.17%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKBAAkebia Therapeutics3.7069 of 5 stars3.62.00.04.01.60.80.6BTMDbiote2.9814 of 5 stars3.53.00.00.00.63.31.3MLYSMineralys Therapeutics2.5594 of 5 stars3.41.00.00.03.14.20.0ZYMEZymeworks2.881 of 5 stars3.54.00.00.01.93.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKBAAkebia Therapeutics 3.20Buy$6.7581.45% UpsideBTMDbiote 3.00Buy$8.00105.66% UpsideMLYSMineralys Therapeutics 2.75Moderate Buy$32.25136.09% UpsideZYMEZymeworks 2.90Moderate Buy$21.0067.06% UpsideCurrent Analyst Ratings BreakdownLatest BTMD, ZYME, AKBA, and MLYS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/3/2025ZYMEZymeworksHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$13.006/17/2025MLYSMineralys TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.006/10/2025MLYSMineralys TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageHold$15.006/4/2025AKBAAkebia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$8.005/20/2025ZYMEZymeworksTD SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/20/2025ZYMEZymeworksTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/14/2025MLYSMineralys TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$48.005/13/2025MLYSMineralys TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.00 ➝ $42.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKBAAkebia Therapeutics$160.18M6.10N/AN/A($0.23) per share-16.17BTMDbiote$199.38M1.07$0.73 per share5.31($2.78) per share-1.40MLYSMineralys TherapeuticsN/AN/AN/AN/A$3.84 per shareN/AZYMEZymeworks$93.38M9.38N/AN/A$6.63 per share1.90Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKBAAkebia Therapeutics-$69.41M-$0.21N/AN/AN/A-24.51%N/A-18.92%8/7/2025 (Estimated)BTMDbiote$3.16M$0.616.387.20N/A10.93%-19.44%20.12%8/6/2025 (Estimated)MLYSMineralys Therapeutics-$177.81M-$3.73N/AN/AN/AN/A-71.15%-65.71%8/12/2025 (Estimated)ZYMEZymeworks-$118.67M-$1.49N/AN/AN/A-182.75%-23.00%-18.04%8/7/2025 (Estimated)Latest BTMD, ZYME, AKBA, and MLYS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025MLYSMineralys Therapeutics-$0.78N/AN/AN/AN/AN/A8/7/2025Q2 2025AKBAAkebia Therapeutics-$0.02N/AN/AN/A$47.60 millionN/A8/7/2025N/AZYMEZymeworks-$0.52N/AN/AN/A$17.18 millionN/A8/6/2025Q2 2025BTMDbiote$0.06N/AN/AN/A$49.52 millionN/A5/12/2025Q1 2025MLYSMineralys Therapeutics-$1.02-$0.79+$0.23-$0.79N/AN/A5/8/2025Q1 2025AKBAAkebia Therapeutics-$0.03$0.03+$0.06$0.03$44.88 million$57.34 million5/8/2025N/AZYMEZymeworks-$0.45-$0.30+$0.15N/A$20.65 million$27.11 million5/7/2025Q1 2025BTMDbiote$0.06$0.08+$0.02$0.37$47.25 million$48.99 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKBAAkebia TherapeuticsN/AN/AN/AN/AN/ABTMDbioteN/AN/AN/AN/AN/AMLYSMineralys TherapeuticsN/AN/AN/AN/AN/AZYMEZymeworksN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKBAAkebia Therapeutics1.892.232.02BTMDbioteN/A1.421.14MLYSMineralys TherapeuticsN/A26.4826.48ZYMEZymeworksN/A4.104.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKBAAkebia Therapeutics33.92%BTMDbiote21.68%MLYSMineralys Therapeutics84.46%ZYMEZymeworks92.89%Insider OwnershipCompanyInsider OwnershipAKBAAkebia Therapeutics3.00%BTMDbiote24.00%MLYSMineralys Therapeutics25.56%ZYMEZymeworks1.92%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKBAAkebia Therapeutics430262.64 million254.76 millionOptionableBTMDbiote19454.71 million41.58 millionNot OptionableMLYSMineralys Therapeutics2865.18 million48.52 millionOptionableZYMEZymeworks46069.68 million67.56 millionOptionableBTMD, ZYME, AKBA, and MLYS HeadlinesRecent News About These CompaniesZymeworks (ZYME) Projected to Post Earnings on ThursdayJuly 31 at 4:18 AM | marketbeat.comBispecific Antibodies Market Report 2025- 2035, with Profiles of Akeso Biopharma, Alexion, Amgen, Genmab, Immunocore, Linton Pharm, Merck, OncXerna Therapeutics, Zymeworks, and ...July 30 at 3:54 PM | finance.yahoo.comFDA Greenlights Trials of Novel ADC and Radiopharmaceutical in Solid TumorsJuly 30 at 5:49 AM | targetedonc.comTZymeworks Inc.: Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug ConjugateJuly 28, 2025 | finanznachrichten.deZymeworks Shares Climb After FDA Clears Investigational New Drug ApplicationJuly 28, 2025 | marketwatch.comZymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug ConjugateJuly 28, 2025 | globenewswire.comZymeworks (NYSE:ZYME) Trading 7% Higher - Should You Buy?July 18, 2025 | marketbeat.comZymeworks (ZYME) Surges 7.1%: Is This an Indication of Further Gains?July 18, 2025 | zacks.comZymeworks Inc. to Release Second Quarter 2025 Financial Results on August 7, 2025July 17, 2025 | quiverquant.comQZymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025July 17, 2025 | financialpost.comFZymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025July 17, 2025 | financialpost.comFZymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025July 17, 2025 | globenewswire.comZymeworks Inc. (NYSE:ZYME) Receives Consensus Rating of "Moderate Buy" from BrokeragesJuly 16, 2025 | marketbeat.comZYME | Zymeworks Inc. Annual Cash Flow Statement | MarketWatchJuly 11, 2025 | marketwatch.comBispecific Antibody Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsightJuly 9, 2025 | finance.yahoo.comZymeworks (NYSE:ZYME) Given "Neutral" Rating at HC WainwrightJuly 3, 2025 | marketbeat.comZymeworks Amends Warrant Agreement with EcoR1 CapitalJune 27, 2025 | tipranks.comZYME - Zymeworks Inc Registered Shs Dividends - MorningstarJune 27, 2025 | morningstar.comMCompanies Like Zymeworks (NASDAQ:ZYME) Are In A Position To Invest In GrowthJune 25, 2025 | finance.yahoo.comAll You Need to Know About Zymeworks (ZYME) Rating Upgrade to BuyJune 20, 2025 | zacks.comZymeworks Inc (NASDAQ:ZYME) Valuation Biotech Sector Trends S&P 500June 18, 2025 | kalkinemedia.comKNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBTMD, ZYME, AKBA, and MLYS Company DescriptionsAkebia Therapeutics NASDAQ:AKBA$3.72 +0.04 (+1.09%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$3.74 +0.02 (+0.54%) As of 08/1/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.biote NASDAQ:BTMD$3.89 -0.18 (-4.42%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$3.89 0.00 (0.00%) As of 08/1/2025 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.Mineralys Therapeutics NASDAQ:MLYS$13.66 -0.49 (-3.46%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$13.67 +0.01 (+0.07%) As of 08/1/2025 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.Zymeworks NYSE:ZYME$12.57 +0.01 (+0.08%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$12.57 0.00 (0.00%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
